Skip to content

Beam Therapeutics BEAM Ratios & Valuation

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Operating margin-226.6%-274.6%-837.1%
EBITDA margin-212.9%-258.6%-797.5%
Free cash flow margin-234%-257.7%-632.6%
Returns
Return on invested capital-39.4%-44.9%-59.3%
Efficiency
Asset turnover0.1×+0.1×0.1×+0.1×-0.2×-0.2×-0.2×
Liquidity
Current ratio17×+8.2×13.1×+8.3×+0.3×6.8×+0.9×8.8×+2.8×
Quick ratio17×+8.2×13.1×+8.3×+0.3×6.8×+0.9×8.8×+2.8×
Cash ratio3.9×+0.1×+1.5×1.5×+0.1×1.6×0.0×3.7×+2.2×
Leverage
Debt-to-equity0.2×+0.1×0.1×-0.1×0.2×0.0×0.1×0.0×0.1×0.0×
Debt-to-assets0.2×+0.1×0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$11.28-12.2%$12.52+40.5%$9.42-1.9%$10.26-1.1%$12.84+14.8%
Valuation
Market capitalization$2.43B+24.5%$2.81B+37.0%$2.46B+21.6%$1.72B-10.6%$1.95B-27.7%
Enterprise value$2.39B+51.2%$2.67B+38.2%$2.34B+19.9%$1.6B-11.3%$1.58B-38.7%
Price / sales14.8×-15.9×20.1×-12.2×44.1×+38.3×28.6×+23.1×30.7×+23.2×
Price / book2.1×+0.4×2.3×-0.5×2.5×0.0×1.6×-0.6×1.7×-1.2×
EV / sales14.6×-10.3×19.1×-11.3×42×+36.4×26.5×+21.4×24.9×+17.7×
Free cash flow yield-15.8%-12.8%-14.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Beam Therapeutics's ratios come from?
Every ratio is computed from Beam Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.